Educational reference only. Not medical advice. Research compounds are not for human or veterinary use.

The benefits of TRT and being hormonally optimized

Testosterone replacement therapy, or TRT, has gone from a niche treatment to something advertised on podcasts and social media. For men who truly have low testosterone, it can make a real difference. It also has real risks, and the evidence is more specific than the marketing suggests. Here is what being "hormonally optimized" actually looks like in the research.

TRT is a prescription therapy. This post is educational: it explains what the large trials found, not how anyone should use testosterone. Starting, adjusting and monitoring it is a job for a licensed clinician.

What testosterone does

Testosterone is the main male sex hormone. It drives sex drive and sperm production, and it helps maintain muscle mass, bone density, red blood cell production, energy and mood. Levels generally drift down slowly with age, and they can fall much faster because of problems with the testes, the pituitary gland, certain medications, obesity or chronic illness.

What low testosterone (hypogonadism) is

Low testosterone, or hypogonadism, is not just a number on a lab report. Both major U.S. guidelines require two things before diagnosing it:

  • Symptoms or signs of deficiency, such as low sex drive, fewer spontaneous erections, loss of body hair, low bone density, unexplained anemia, fatigue or low mood.
  • Consistently low blood levels. The Endocrine Society recommends measuring total testosterone on two separate mornings while fasting, using an accurate, certified lab test. The American Urological Association calls a total testosterone below 300 ng/dL a reasonable cut-off and also asks for two early-morning readings on different days.

Testosterone naturally peaks in the morning and can dip for a day or two after illness, poor sleep or heavy drinking, which is why one low reading is not enough. A good workup also looks for the cause, because low testosterone can be a sign of another problem, such as a pituitary condition, that needs its own treatment.

Neither guideline supports screening every man, and the Endocrine Society suggests against routinely prescribing testosterone to all men 65 and older with low levels. Treatment is meant for men with a real, confirmed deficiency.

The real benefits: what the big trials show

Two large, placebo-controlled research programs give the clearest picture. The Testosterone Trials followed 790 men aged 65 and older with low testosterone for a year. TRAVERSE followed 5,246 men aged 45 to 80 with low testosterone and heart disease or high heart risk for an average of almost three years.

Sexual function: the most consistent benefit

  • In the Testosterone Trials, sexual activity, sexual desire and erectile function all improved more with testosterone than with placebo.
  • In a TRAVERSE study of 1,161 men with low libido, testosterone improved sexual activity and desire, and the effect lasted through two years. Erectile function did not improve in that study.

Red blood cells and anemia

Testosterone stimulates red blood cell production. In TRAVERSE, among men who were anemic at the start, 45% on testosterone were no longer anemic after a year, compared with 34% on placebo, and fewer men on testosterone developed new anemia. The Testosterone Trials found similar results in older men with unexplained anemia.

Bone density

In the Testosterone Trials bone study, spine bone density rose 7.5% with testosterone versus 0.8% with placebo, and estimated bone strength rose as well. But higher density did not translate into fewer fractures: in TRAVERSE, clinical fractures were actually somewhat more common with testosterone (3.5% versus 2.5%). Testosterone should not be thought of as fracture protection.

Mood

The Testosterone Trials found small improvements in mood and depressive symptoms. In TRAVERSE, about half of the men had significant depressive symptoms at the start, and testosterone gave a modest but real improvement in mood. It did not show a benefit in the small group with a persistent low-grade depressive disorder, and it is not a substitute for depression treatment.

Body composition

A 2016 meta-analysis of placebo-controlled trials in men with hypogonadism found that testosterone increased lean body mass by about 1.2 kg on average. Fat mass trended down by a little under 1 kg, but that change was not statistically significant. In other words, the muscle effect is real but modest, and TRT is not a fat-loss treatment.

Where it did not help

  • Energy and fatigue: In the Testosterone Trials, vitality scores did not improve.
  • Walking and physical function: Results were mixed and small.
  • Memory and thinking: The cognition trial found no benefit.
  • Diabetes prevention: In TRAVERSE, testosterone did not reduce progression from prediabetes to diabetes.

Heart safety: what TRAVERSE settled

For years the biggest question was whether TRT raises the risk of heart attack and stroke. TRAVERSE was designed to answer it. Major cardiac events (heart attack, stroke or cardiovascular death) occurred in 7.0% of men on testosterone and 7.3% on placebo, meeting the trial's test for safety. In February 2025 the FDA removed the cardiovascular language from the boxed warning on testosterone labels as a result.

TRAVERSE did find more atrial fibrillation (3.5% versus 2.4%), acute kidney injury and pulmonary embolism with testosterone. And in an earlier Testosterone Trials substudy, men on testosterone had a larger increase in noncalcified coronary plaque volume than men on placebo. Heart safety is reassuring overall, not a blank check.

The risks and the monitoring that comes with TRT

  • Thicker blood. Rising hematocrit (the share of blood made of red cells) is one of the most common problems. The Endocrine Society advises checking it at 3 to 6 months, at 12 months and then yearly, and holding treatment if it rises above 54%.
  • Blood pressure. The FDA now requires a blood pressure warning on all testosterone products after monitoring studies confirmed testosterone raises blood pressure.
  • Fertility. This is the risk most often left out of the sales pitch. Outside testosterone signals the brain to shut down the hormones that drive sperm production. In a World Health Organization study of 271 men given weekly testosterone, 65% had no sperm in their semen within six months. Most recovered after stopping, but recovery can take months and is not always complete. The 2024 guideline from the American Urological Association and the American Society for Reproductive Medicine says men interested in having children now or in the future should not be prescribed testosterone.
  • Prostate. In TRAVERSE, prostate cancer rates were low and similar in both groups, and PSA rose only slightly. Monitoring is still standard, especially for men 55 to 69.
  • Who should not start. The Endocrine Society lists men planning a pregnancy soon, men with breast or prostate cancer, an elevated hematocrit, untreated severe sleep apnea, uncontrolled heart failure, a heart attack or stroke in the past six months, or a clotting disorder, among others.

What "hormonally optimized" should mean

The guidelines aim to bring a deficient man's testosterone into the mid-normal range for healthy young men. That is replacement. Pushing levels far above normal, or treating men whose levels are already normal, is not supported by any guideline, and the benefits above were shown in men with confirmed deficiency, not in men chasing a number.

That distinction matters because not every clinic draws the line. In a 2022 "secret shopper" study, a researcher posed as a 34-year-old man with normal testosterone who wanted children in the future. Six of seven online testosterone platforms offered him treatment anyway, only one asked about fertility, and half quoted target levels above 1,000 ng/dL without discussing the fertility risk.

Being optimized, in the sense the evidence supports, means a confirmed diagnosis, a clear goal, the lowest level of intervention that gets there and regular monitoring by a clinician who knows your full picture.

Regulatory status

  • Testosterone is an FDA-approved prescription drug and a Schedule III controlled substance in the United States.
  • In February 2025 the FDA added the TRAVERSE results to all testosterone labels, removed the boxed cardiovascular warning language and added class-wide blood pressure warnings.
  • In June 2026 HHS asked manufacturers to make further label changes, including removing the limitation on use for age-related low testosterone. As of this writing those changes were requested, not finalized.

Key references

This post is educational and is not medical advice. It does not give dosing guidance. Testosterone is a prescription drug; talk to a licensed clinician about whether testing or treatment is right for you.

Educational content only

Peptide Knowledge is an educational reference. Nothing on this site is medical advice, a treatment recommendation or dosing guidance. Many compounds described here are not approved for human use and are sold for laboratory research only. Talk to a licensed clinician before starting, stopping or changing any medication or supplement.

All blog posts